BioLineRx Ltd. (BLRX)

BioLineRx Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	11.66	4.8	0	0	0	0
Cost of Revenue	5.15	3.69	0	0	0	0
Gross Profit	6.51	1.11	0	0	0	0
Selling, General & Admin	34.14	31.58	11.53	5.31	4.75	4.67
Research & Development	11.33	12.52	17.63	19.47	18.17	23.44
Other Operating Expenses	6.7	6.7	0	0	0	0
Operating Expenses	52.17	50.8	29.16	24.78	22.93	28.11
Operating Income	-45.66	-49.69	-29.16	-24.78	-22.93	-28.11
Interest Expense / Income	2.17	2.17	2.16	1.01	1.63	2.28
Other Expense / Income	1.32	8.75	-6.36	1.27	5.47	-4.94
Pretax Income	-49.15	-60.61	-24.95	-27.05	-30.02	-25.45
Net Income	-49.15	-60.61	-24.95	-27.05	-30.02	-25.45
Shares Outstanding (Basic)	1,087	963	774	663	253	146
Shares Outstanding (Diluted)	1,087	963	774	663	253	146
Shares Change	17.73%	24.47%	16.75%	162.19%	72.70%	34.82%
EPS (Basic)	-0.05	-0.06	-0.03	-0.04	-0.12	-0.17
EPS (Diluted)	-0.05	-0.06	-0.03	-0.04	-0.12	-0.17
Free Cash Flow	-28.82	-22.72	-26.37	-23.67	-23.21	-22.73
Free Cash Flow Per Share	-0.40	-0.35	-0.51	-0.54	-1.38	-2.33
Gross Margin	55.84%	23.08%	-	-	-	-
Operating Margin	-391.76%	-1035.29%	-	-	-	-
Profit Margin	-421.69%	-1262.79%	-	-	-	-
Free Cash Flow Margin	-247.25%	-473.42%	-	-	-	-
EBITDA	-44.96	-57.06	-22.14	-25.35	-27.46	-22.23
EBITDA Margin	-385.71%	-1188.77%	-	-	-	-
Depreciation & Amortization	2.02	1.38	0.65	0.7	0.93	0.94
EBIT	-46.98	-58.45	-22.79	-26.05	-28.39	-23.17
EBIT Margin	-403.06%	-1217.60%	-	-	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).